Open AccessTargeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas
Author(s) -
Vivian T. Yin,
Helen Merritt,
Bita Esmaeli
Publication year - 2014
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v2.i9.432
Subject(s) - medicine , vismodegib , basal cell carcinoma , tolerability , eyelid , oncology , hedgehog signaling pathway , dermatology , cancer research , radiation therapy , targeted therapy , basal cell , surgery , cancer , adverse effect , signal transduction , biochemistry , chemistry
For patients with metastatic or locally advanced eyelid and periocular carcinoma not amenable to surgical excision, targeted therapies have shown efficacy with better tolerability compared to cytotoxic chemotherapy. Overexpression of epithelial growth factor receptor was found in squamous cell carcinomas. Vismodegib targets the mutation in the hedgehog pathway identified in basal cell carcinoma and basal cell nevus syndrome. Targeted therapies provide a novel and potentially effective treatment alternative for patients with eyelid carcinoma not amendable for surgery, including those with metastatic, locally advanced disease, advanced age, and significant comorbidities. High cost, need for long-term treatment, and toxicity are relative limitations.